FDA Draft Guidance Aims to Streamline Individualized Gene Therapy Approvals

Key points

• FDA published draft guidance on October 27 to streamline approvals for individualized gene therapies.
• The guidance allows institutions to use existing Biological License Applications without new clinical data for each patient.
• CMS plans to expand partnerships with drugmakers to cover more rare disorders and offer states better pricing.
• Acting FDA Commissioner Kyle Diamantas stated that only 5% of rare diseases have approved treatments.
• Former FDA officials argue that current proposals lack a clear regulatory pathway and need molecular-based indications.
• The initiative aims to make individualized therapies commercially viable and accessible for rare disease patients.

Background

Recent approvals for gene therapies, such as Genglycos for glycogen storage disease and Fayuvi for Sanfilippo syndrome, have highlighted the potential of these treatments. However, the high costs and complex approval processes have limited access. The FDA's new draft guidance is part of a broader effort to address these challenges and improve access to rare disease treatments.

How outlets are covering it

STAT reported that rare disease advocates applauded the FDA's effort to ease access to custom treatments. BioCentury, through former FDA official Janet Woodcock, argued that the FDA needs a new paradigm to unlock therapies for rare diseases, including defining indications by molecular defect and approving platforms that accommodate individualized treatments. Politico highlighted that the FDA is getting a boost from public gatherings amplifying patient voices and policymakers' agendas. Ideastream reported that Dr. Mehmet Oz and Acting FDA Commissioner Kyle Diamantas explained how new federal guidelines would ease approval of gene therapy treatments for people with rare diseases.

Why it matters

The FDA's draft guidance could significantly impact the development and approval of individualized gene therapies, potentially making them more accessible and commercially viable for rare disease patients. The initiative aims to address the long-standing challenges of slow approval processes and high costs, which have limited access to these treatments. By streamlining the approval process and expanding Medicaid coverage, the FDA and CMS hope to improve outcomes for patients with rare diseases.

What to watch

The FDA will host a public meeting on October 28 to gather feedback on the framework initiative. CMS plans to expand current partnerships with drugmakers to cover treatments for other rare disorders. The FDA and CMS will continue to work on implementing the draft guidance and addressing the challenges of individualized gene therapy approvals.